Smoking as a risk for CAD : The KMIC Study

지선하 한국지질학회 1999 韓國脂質學會誌 Vol.9 No.3

유전역학적 연구방법:유전자 분리모형 분석

지선하 한국역학회 1997 Epidemiology and Health Vol.19 No.2

한국역학회 : 아버지의 흡연과 자녀들의 호흡기질환 이환률 및 치료기간

지선하,서일,김일순 대한보건협회 1993 대한보건협회 보건종합학술대회 Vol.- No.-

Cohort and prognosis study design

지선하 대한간학회 2012 임상연구방법론워크숍 Vol.2012 No.1

한 종합병원 임상병리과의 시약 관리현황과 개선방안

지선하,이삼열,유승흠,양용석,Ji, Seon-Ha,Lee, Sam-Yeol,Yu, Seung-Heum,Yang, Yong-Seok 대한병원협회 1988 대한병원협회지 Vol.17 No.9

전국 중, 고등학교 흡연실태 설문조사의 조사-재조사 신뢰도 평가

지선하,윤지은,원소영,김수정,서일 한국역학회 2003 Epidemiology and Health Vol.25 No.1

Purpose : Since 1988, the annual or biannual survey was conducted by Korean Association of Smoking and Health (KASH) to examine the smoking rate, knowledge and attitude on smoking of students attending middle and high school in Korea. The objective of this study was to investigate the test-retest reliability of self-administered smoking questionnaire for Korean middle and high school students. Methods : For the test-retest study, we sampled 30 school among 106 schools which participated in annual survey on June of 2002. Among 30 schools, 26 schools (86.7%) were responded for this study. Results : 1) For the subjects of 1st and 2nd surveys, there were no difference on smoking related variable including attitude, knowledge, perceived health status, father's smoking status, friend's smoking status, willingness to smoke, and readiness to quit smoking 2) For middle school students among male, current smoking rates were 3.5% for 1st survey and 3.0% for 2nd survey, which was statistically no significant. For high school students, however, current smoking rate of 1st survey was higher (21.1%) than that of 2nd (18.2%), although the rate was not significantly differed. 3) For middle school students among female, current smoking rates were 1.1% for 1st survey and 3.3% for 2nd survey, which was statistically no significant. Corresponding rate for high school students were 9.8% and 11.4%, respectively. Conclusion : The results indicated that smoking questionnaire has been conducted by KASH is reliable for use in estimation for prevalence of smoking for middle and high school students.

Obesity, Insulin Resistance and Cancer Risk

지선하,김희진,이자경 연세대학교의과대학 2005 Yonsei medical journal Vol.46 No.4

Obesity is a known cause of metabolic syndrome which includes Type II diabetes, hypertension, and dyslipidemia. It is well documented that insulin resistance contributes to the mortality and the incidence of metabolic syndromes including central obesity, dyslipidemia, hyperglycemia and hypertension. Both obesity and diabetes are emerging topics for researchers to consider as having a possible causal association with cancer since the two factors have been viewed as risk factors for cancer. The present paper introduced the hypothesis of a possible causal relationship between obesity, insulin resistance and cancer and reviews relevant existing studies in this area. More efforts and studies are needed to clarify the mechanisms and the common risk factors which might be incorporated into interventions to prevent cancer and cardiovascular diseases as top causes of death.

Serum Adiponectin and Type 2 Diabetes: A 6-Year Follow-Up Cohort Study

지선하,안철우,박종숙,박창규,김현숙,이상학,박성하,이명숙,이창범,박혜순,김희진,최성희,성지동,오승준,정효지,김성래,윤호정,김선미,이홍수,목예진,최은미,윤영덕,백수진,주재성,허갑범 대한당뇨병학회 2013 Diabetes and Metabolism Journal Vol.37 No.4

Background: Studies on factors which may predict the risk of diabetes are scarce. This prospective cohort study was conducted to determine the association between adiponectin and type 2 diabetes among Korean men and women. Methods: A total of 42,845 participants who visited one of seven health examination centers located in Seoul and Gyeonggi province, Republic of Korea between 2004 and 2008 were included in this study. The incidence rates of diabetes were determined through December 2011. To evaluate the effects of adiponectin on type 2 diabetes, the Cox proportional hazard model was used. Results: Of the 40,005 participants, 959 developed type 2 diabetes during a 6-year follow-up. After the adjustment for age, body mass index (BMI), and waist circumference, the risks for type 2 diabetes in participants with normoglycemia had a 1.70-fold (95% confidence interval [CI], 1.21 to 2.38) increase in men and a 1.83-fold (95% CI, 1.17 to 2.86) increase in women with the lowest tertile of adiponectin when compared to the highest tertile of adiponectin. For participants with impaired fasting glucose (IFG), the risk for type 2 diabetes had a 1.46-fold (95% CI, 1.17 to 1.83) increase in men and a 2.52-fold (95% CI, 1.57 to 4.06) increase in women with the lowest tertile of adiponectin. Except for female participants with normoglycemia, all the risks remained significant after the adjustment for fasting glucose and other confounding variables. Surprisingly, BMI and waist circumference were not predictors of type 2 diabetes in men or women with IFG after adjustment for fasting glucose and other confounders. Conclusion: A strong association between adiponectin and diabetes was observed. The use of adiponectin as a predictor of type 2 diabetes is considered to be useful.

Linkage of Epidemiologic Evidence With the Clinical Aspects of Metabolic Syndrome

지선하,조재성 대한심장학회 2012 Korean Circulation Journal Vol.42 No.6

Metabolic syndrome (MetS) is characterized by a cluster of cardiovascular risk factors, such as hypertension, glucose intolerance, high tri-glycerides, and a low high density lipoprotein-cholesterol level. MetS is known to be associated with cardiovascular diseases. In order to diagnose MetS, definitions such as National Cholesterol Education Program Adult Treatment Panel III, American Heart Association/Na -tional Heart Lung and Blood Institute, International Diabetes Federation, World Health Organization, European Group for the Study of Insu-lin Resistance and American College of Endocrinology are widely used. However, using different criteria may lead to confusion regarding the diagnosis and treatment of patients with MetS in the primary care setting. Our objected was to review 3 aspects concerning MetS us-ing the Metabolic Syndrome Research Initiatives study of 123892 healthy Koreans (1994-2001) that had a maximum follow-up of 12 years. The 3 aspects were reviewed by determination of the association of MetS with the development of atherosclerotic cardiovascular disease (ASCVD) and ischemic heart disease (IHD). Based on our findings, each metabolic factor associated with MetS was not weighted equally. The hazard ratio (HR) was higher in individuals with higher glucose compared with the HR in individuals with higher body mass index. In-dividuals with pre-MetS (having 1 or 2 metabolic factors) had 1.5-2.3 fold higher risk of developing ASCVD and IHD in both genders. In the pres-ence of MetS, both singly and in combination, precede the development of ASCVD and IHD and individuals with pre-MetS must not be ig-nored as there is no apparent threshold in defining MetS. Furthermore, MetS may complement the Framingham Risk Score and can be used as the first line approach to treat the ASCVD or IHD. Metabolic syndrome (MetS) is characterized by a cluster of cardiovascular risk factors, such as hypertension, glucose intolerance, high tri-glycerides, and a low high density lipoprotein-cholesterol level. MetS is known to be associated with cardiovascular diseases. In order to diagnose MetS, definitions such as National Cholesterol Education Program Adult Treatment Panel III, American Heart Association/Na -tional Heart Lung and Blood Institute, International Diabetes Federation, World Health Organization, European Group for the Study of Insu-lin Resistance and American College of Endocrinology are widely used. However, using different criteria may lead to confusion regarding the diagnosis and treatment of patients with MetS in the primary care setting. Our objected was to review 3 aspects concerning MetS us-ing the Metabolic Syndrome Research Initiatives study of 123892 healthy Koreans (1994-2001) that had a maximum follow-up of 12 years. The 3 aspects were reviewed by determination of the association of MetS with the development of atherosclerotic cardiovascular disease (ASCVD) and ischemic heart disease (IHD). Based on our findings, each metabolic factor associated with MetS was not weighted equally. The hazard ratio (HR) was higher in individuals with higher glucose compared with the HR in individuals with higher body mass index. In-dividuals with pre-MetS (having 1 or 2 metabolic factors) had 1.5-2.3 fold higher risk of developing ASCVD and IHD in both genders. In the pres-ence of MetS, both singly and in combination, precede the development of ASCVD and IHD and individuals with pre-MetS must not be ig-nored as there is no apparent threshold in defining MetS. Furthermore, MetS may complement the Framingham Risk Score and can be used as the first line approach to treat the ASCVD or IHD.

한국인의 금연 실태

지선하 대한결핵협회 1999 보건세계 Vol.46 No.6